BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32577374)

  • 1. CSF3R truncation mutations in a patient with B-cell acute lymphoblastic leukemia and a favorable response to chemotherapy plus dasatinib.
    Schwartz MS; Wieduwilt MJ
    Leuk Res Rep; 2020; 14():100208. PubMed ID: 32577374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies.
    Kim SY; Song IC; Kim J; Kwon GC
    Ann Diagn Pathol; 2024 Apr; 71():152317. PubMed ID: 38642470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.
    Maxson JE; Luty SB; MacManiman JD; Paik JC; Gotlib J; Greenberg P; Bahamadi S; Savage SL; Abel ML; Eide CA; Loriaux MM; Stevens EA; Tyner JW
    Clin Cancer Res; 2016 Feb; 22(3):757-64. PubMed ID: 26475333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a novel CSF3R-SPTAN1 fusion gene in an atypical chronic myeloid leukemia patient with t(1;9)(p34;q34) by RNA-Seq.
    Sheng G; Zhang J; Zeng Z; Pan J; Wang Q; Wen L; Xu Y; Wu D; Chen S
    Cancer Genet; 2017 Oct; 216-217():16-19. PubMed ID: 29025591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.
    Pardanani A; Lasho TL; Laborde RR; Elliott M; Hanson CA; Knudson RA; Ketterling RP; Maxson JE; Tyner JW; Tefferi A
    Leukemia; 2013 Sep; 27(9):1870-3. PubMed ID: 23604229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-Occurring CSF3R W791* Germline and Somatic T618I Driver Mutations Induce Early CNL and Clonal Progression to Mixed Phenotype Acute Leukemia.
    Adam FC; Szybinski J; Halter JP; Cantoni N; Wenzel F; Leonards K; Brkic S; Passweg JR; Touw I; Maxson JE; Meyer SC
    Curr Oncol; 2022 Feb; 29(2):805-815. PubMed ID: 35200567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
    Dao KT; Gotlib J; Deininger MMN; Oh ST; Cortes JE; Collins RH; Winton EF; Parker DR; Lee H; Reister A; Schultz ; Savage S; Stevens ; Brockett C; Subbiah N; Press RD; Raess PW; Cascio M; Dunlap J; Chen Y; Degnin C; Maxson JE; Tognon CE; Macey T; Druker BJ; Tyner JW
    J Clin Oncol; 2020 Apr; 38(10):1006-1018. PubMed ID: 31880950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
    Maxson JE; Gotlib J; Pollyea DA; Fleischman AG; Agarwal A; Eide CA; Bottomly D; Wilmot B; McWeeney SK; Tognon CE; Pond JB; Collins RH; Goueli B; Oh ST; Deininger MW; Chang BH; Loriaux MM; Druker BJ; Tyner JW
    N Engl J Med; 2013 May; 368(19):1781-90. PubMed ID: 23656643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation sequencing reveals unique combination of mutations in cis of CSF3R in atypical chronic myeloid leukemia.
    Yun JW; Yoon J; Jung CW; Lee KO; Kim JW; Kim SH; Kim HJ
    J Clin Lab Anal; 2020 Feb; 34(2):e23064. PubMed ID: 31692115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colony-stimulating factor 3 receptor (CSF3R) M696T mutation does not impact on clinical outcomes of a Ph+ acute lymphoblastic leukemia patient.
    Chen X; Wang B; Pang A; Yuan W; Jiang E; Chu Y; Feng S; Han M
    Blood Sci; 2021 Jul; 3(3):87-92. PubMed ID: 35402839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia.
    Khanna V; Pierce ST; Dao KH; Tognon CE; Hunt DE; Junio B; Tyner JW; Druker BJ
    Cureus; 2015 Dec; 7(12):e414. PubMed ID: 26870618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice.
    Tefferi A; Elliott M; Pardanani A
    Curr Opin Hematol; 2015 Mar; 22(2):171-6. PubMed ID: 25575036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.
    Dao KH; Solti MB; Maxson JE; Winton EF; Press RD; Druker BJ; Tyner JW
    Leuk Res Rep; 2014; 3(2):67-9. PubMed ID: 25180155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What's different about atypical CML and chronic neutrophilic leukemia?
    Dao KH; Tyner JW
    Hematology Am Soc Hematol Educ Program; 2015; 2015():264-71. PubMed ID: 26637732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
    Dao KT; Tyner JW; Gotlib J
    Curr Hematol Malig Rep; 2017 Oct; 12(5):432-441. PubMed ID: 28983816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].
    Senín A; Arenillas L; Martínez-Avilés L; Fernández-Rodríguez C; Bellosillo B; Florensa L; Besses C; Álvarez-Larrán A
    Med Clin (Barc); 2015 Jun; 144(11):487-90. PubMed ID: 24854193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
    Ouyang Y; Qiao C; Chen Y; Zhang SJ
    Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Management of Chronic Neutrophilic Leukemia.
    Szuber N; Tefferi A
    Curr Treat Options Oncol; 2021 Jun; 22(7):59. PubMed ID: 34097138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonal evolution in a chronic neutrophilic leukemia patient.
    Zhang QG; Wang J; Gong WY; Jing QC
    Hematology; 2019 Dec; 24(1):455-458. PubMed ID: 31076019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes.
    Carreño-Tarragona G; Álvarez-Larrán A; Harrison C; Martínez-Ávila JC; Hernández-Boluda JC; Ferrer-Marín F; Radia DH; Mora E; Francis S; González-Martínez T; Goddard K; Pérez-Encinas M; Narayanan S; Raya JM; Singh V; Gutiérrez X; Toth P; Amat-Martínez P; Mcilwaine L; Alobaidi M; Mayani K; McGregor A; Stuckey R; Psaila B; Segura A; Alvares C; Davidson K; Osorio S; Cutting R; Sweeney CP; Rufián L; Moreno L; Cuenca I; Smith J; Morales ML; Gil-Manso R; Koutsavlis I; Wang L; Mead AJ; Rozman M; Martínez-López J; Ayala R; Cross NCP
    Blood Adv; 2023 May; 7(9):1672-1681. PubMed ID: 36375042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.